DE69905712T2 - Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen - Google Patents

Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen Download PDF

Info

Publication number
DE69905712T2
DE69905712T2 DE69905712T DE69905712T DE69905712T2 DE 69905712 T2 DE69905712 T2 DE 69905712T2 DE 69905712 T DE69905712 T DE 69905712T DE 69905712 T DE69905712 T DE 69905712T DE 69905712 T2 DE69905712 T2 DE 69905712T2
Authority
DE
Germany
Prior art keywords
inhibiting
bisindoles
cycline
indigo
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69905712T
Other languages
English (en)
Other versions
DE69905712D1 (de
Inventor
Gerhard Eisenbrand
Doris Marko
Weici Tang
Laurent Meijer
Ralph Hoessl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98109845A external-priority patent/EP0966963A1/de
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE69905712D1 publication Critical patent/DE69905712D1/de
Application granted granted Critical
Publication of DE69905712T2 publication Critical patent/DE69905712T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69905712T 1998-05-29 1999-05-26 Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen Expired - Fee Related DE69905712T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98109845A EP0966963A1 (de) 1998-05-29 1998-05-29 Verwendung von indigoähnliche bisindole als CDK1-hemmer
EP99105693 1999-03-19
PCT/EP1999/003625 WO1999062503A2 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases

Publications (2)

Publication Number Publication Date
DE69905712D1 DE69905712D1 (de) 2003-04-10
DE69905712T2 true DE69905712T2 (de) 2004-01-29

Family

ID=26149292

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69905712T Expired - Fee Related DE69905712T2 (de) 1998-05-29 1999-05-26 Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen

Country Status (14)

Country Link
EP (1) EP1079826B1 (de)
JP (1) JP2002516851A (de)
KR (1) KR20010078722A (de)
AT (1) ATE233560T1 (de)
AU (1) AU762830B2 (de)
BR (1) BR9910810A (de)
CA (1) CA2333661A1 (de)
DE (1) DE69905712T2 (de)
DK (1) DK1079826T3 (de)
ES (1) ES2194468T3 (de)
HU (1) HUP0102240A3 (de)
IL (1) IL139914A0 (de)
NO (1) NO20006027L (de)
WO (1) WO1999062503A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
PL351261A1 (en) 1999-04-12 2003-04-07 Gerhard Eisenbrand Derivatives of indigoid bisindoles
EP1218004B1 (de) 1999-04-12 2009-04-08 Heinz Herbert Fiebig 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren
AU2002213132A1 (en) * 2000-10-10 2002-04-22 Board Of Regents, The University Of Texas System Suppression of cyclin kinase activity for prevention and treatment of infections
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
WO2002059123A2 (en) * 2000-12-18 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
FR2821358B1 (fr) * 2001-02-27 2006-04-07 Aventis Pharma Sa Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
JP2005516938A (ja) * 2001-12-13 2005-06-09 ナトロジェン・セラピューティクス・インコーポレーテッド イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
AU2003228427B2 (en) * 2002-04-03 2009-07-02 Allergan, Inc. (3Z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
CN1199946C (zh) * 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
CA2566396A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN1329376C (zh) * 2005-09-19 2007-08-01 无锡杰西医药科技有限公司 一种n（1）－烃基－3′－肟基靛玉红衍生物（i）的制备方法及其医学应用
JP4587961B2 (ja) * 2006-01-16 2010-11-24 独立行政法人科学技術振興機構 神経因性疼痛治療剤
EP2379549B1 (de) 2008-12-22 2016-09-21 Eisenbrand, Gerhard 7-azaindirubine, 7'-azainrubine, 7-7'-diazainrubin und entsprechende 3'-oximetherderivate: herstellung davon, herstellung und verwendung als medikament
EP2199292A1 (de) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubine, 7'-azainrubine, 7-7'-diazainrubin und entsprechende 3'-oximetherderivate: Herstellung davon, Herstellung und Verwendung als Medikament
FR2945747A1 (fr) 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
FR2952818B1 (fr) * 2009-11-23 2013-05-31 Oreal Composition contenant au moins un precurseur de coloration derive d'indole, au moins un colorant indoline dione et au moins un compose organique liquide
KR101180030B1 (ko) * 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
US8524121B2 (en) * 2012-01-27 2013-09-03 Xerox Corporation Bi-indoline-dithione polymers
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
CN113773243B (zh) * 2021-09-01 2023-01-06 大连理工大学 一种有机催化氧化吲哚自缩合制备异靛蓝类化合物的方法
MX2024004264A (es) 2021-10-08 2024-07-10 Azora Therapeutics Inc Derivados de agonistas de los receptores de aril hidrocarburos.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Also Published As

Publication number Publication date
AU4368799A (en) 1999-12-20
JP2002516851A (ja) 2002-06-11
CA2333661A1 (en) 1999-12-09
BR9910810A (pt) 2001-02-13
NO20006027L (no) 2001-01-22
ATE233560T1 (de) 2003-03-15
EP1079826B1 (de) 2003-03-05
DE69905712D1 (de) 2003-04-10
AU762830B2 (en) 2003-07-03
ES2194468T3 (es) 2003-11-16
IL139914A0 (en) 2002-02-10
HUP0102240A3 (en) 2003-05-28
WO1999062503A3 (en) 2000-01-27
WO1999062503A2 (en) 1999-12-09
KR20010078722A (ko) 2001-08-21
HUP0102240A2 (hu) 2001-11-28
EP1079826A2 (de) 2001-03-07
NO20006027D0 (no) 2000-11-28
DK1079826T3 (da) 2003-06-23

Similar Documents

Publication Publication Date Title
DE69905712D1 (de) Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen
RS94703A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
WO1999057117A3 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
YU59800A (sh) Supstituisani indolinoni sa inhibitorskim dejstom na kinaze i ciklin /cdk komplekse
UY27592A1 (es) Nuevo uso
ID27757A (id) Indolinona-indolinona tersubstitusi baru, preparasi dan penggunaannya sebagai obat
EE9900465A (et) Uued ühendid
BR0312633A (pt) Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto
SE0104341D0 (sv) New use
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
DE69928235D1 (de) Cyclin-abhängige kinase inhibitoren
NZ335253A (en) certain [9-(cycloalkylmethyl or phenylmethyl)-5-carbamoyl-carbazol-4-yl]oxyacetic acid derivatives
GEP20032913B (en) Thienylazolylalcoxyethanamines, Their Preparation and Their Application as Medicaments
AU2001295482A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
SE8703169L (sv) 1-(4-aminofenyl)-4-metyl-7,8-metylendioxi-3,4-dihydro-5h-2,3-bensodiazepin, syraadditionssalter derav samt forfarande for framstellning av densamma
AU2502997A (en) New 2,3-benzodiazepine derivatives, their production and use as pharmaceutical agents
HUP0203045A2 (hu) Epesavval képezett 4-benzil-amino-kinolin konjugátumok és hetero-analógjai, valamint eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények, és ezek alkalmazása
HUP9701284A2 (hu) 2,3-Benzodiazepin-származékok felhasználása az endogén opioid rendszerrel összefüggő betegségek és állapotok kezelésére, és megelőzésére alkalmas gyógyászati készítmények előállítására
MY134141A (en) "glyoxal-phenolic condensates with enhanced fluoroescence"
FR2824829B1 (fr) Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
DE60326731D1 (de) Arzneizubereitung und deren anwendung zur behandlu
HU9502647D0 (en) Benzo[f]quinoxalindione derivatives, their preparation and their use in drugs
DE60112253D1 (de) Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee